Demant kommer med halv\u00e5rsregnskab i morgen efter en markant vending i aktien siden for\u00e5ret. En vigtig del af optimismen h\u00e6nger sammen med GN Store Nords aftale om at s\u00e6lge GN Hearing til italienske Amplifon for 17 mia. kr. Handlen ventes f\u00f8rst afsluttet mod slutningen af 2026, men usikkerheden hos en af Demants st\u00f8rste konkurrenter giver allerede nu selskabet en mulighed for, at styrke sin position yderligere.<\/p>\n
Og f\u00f8rste kvartal viste faktisk, at Demant allerede var godt p\u00e5 vej. Demants Hearing Aids-forretning leverede 9 pct. organisk v\u00e6kst mod et globalt marked, som selskabet vurderede voksede omkring 4 pct. m\u00e5lt i v\u00e6rdi. Det bet\u00f8d if\u00f8lge Demant betydelige markedsandelsgevinster, is\u00e6r drevet af Oticon Zeal. Regnskabet skal nu vise, om det momentum er fortsat ind i andet kvartal.<\/p>\n
AI er samtidig allerede blevet en reel del af produktet. Oticon Zeal bruger anden generation af AI-baseret lydbehandling, der kontinuerligt tilpasser st\u00f8jreduktion og taleforst\u00e5else. Produktet kombinerer samtidig genopladelighed, streaming og Google Fast Pair i et diskret in-ear-format. For investorerne bliver det interessant at holde \u00f8je med, fordi Demant dermed ikke kun konkurrerer p\u00e5 klassisk h\u00f8reapparatteknologi, men ogs\u00e5 p\u00e5 brugeroplevelse og digital integration.<\/p>\n
Det bliver stadig vigtigere. Apple tilbyder allerede en regulatorisk godkendt hearing-aid-funktion i AirPods Pro til personer med mildt til moderat h\u00f8retab. Det betyder ikke, at traditionelle h\u00f8reapparater forsvinder, men det reducerer afstanden mellem medicinsk udstyr og consumer electronics. For Demant bliver sp\u00f8rgsm\u00e5let derfor ikke kun, hvor sm\u00e5 h\u00f8reapparaterne kan blive, men hvor godt de kan integreres med den digitale hverdag.\u202fDet kan p\u00e5 l\u00e6ngere sigt blive afg\u00f8rende for b\u00e5de v\u00e6kst og priss\u00e6tning.<\/p>\n
Halv\u00e5rsregnskabet skal derfor f\u00f8rst og fremmest bekr\u00e6fte, at Demant fortsat tager markedsandele. Efter aktiens comeback er forventningerne ogs\u00e5 l\u00f8ftet, og dermed er der mindre plads til skuffelser. Hvis v\u00e6ksten fortsat ligger klart over markedet, styrker det investeringscasen. Hvis momentum derimod aftager, kan markedet hurtigt begynde at stille sp\u00f8rgsm\u00e5l ved, hvor meget af fremgangen der skyldes Demants egen styrke, og hvor meget der skyldes uro hos konkurrenterne. P\u00e5 l\u00e6ngere sigt bliver produktpipeline, AI og samarbejdet med de store teknologiplatforme mindst lige s\u00e5 vigtigt.<\/p>\n
Demant has gained momentum \u2013 now the market share gains need to be confirmed<\/b><\/p>\n
Demant reports its half-year results tomorrow after a significant recovery in the share price since the spring. An important part of the optimism is linked to GN Store Nord\u2019s agreement to sell GN Hearing to Italy\u2019s Amplifon for DKK 17 billion. The transaction is expected to be completed toward the end of 2026, but uncertainty around one of Demant\u2019s major competitors is already giving the company an opportunity to strengthen its position further.<\/p>\n
And the first quarter actually showed that Demant was already on the right track. Demant\u2019s Hearing Aids business delivered 9% organic growth versus a global market that the company estimated grew around 4% in value. That resulted in significant market share gains, particularly driven by Oticon Zeal. The upcoming report will now show whether that momentum continued into the second quarter.<\/p>\n
AI has also already become a real part of the product offering. Oticon Zeal uses second-generation AI-based sound processing that continuously adjusts noise reduction and speech understanding. The product also combines rechargeability, streaming and Google Fast Pair in a discreet in-ear format. For investors, this will be interesting to follow because it moves Demant closer to traditional headphone technology, while also testing the level of digital integration.<\/p>\n
That is becoming increasingly important. Apple already offers a regulatory-approved hearing aid feature in AirPods Pro for people with mild to moderate hearing loss. This does not mean that traditional hearing aids are disappearing, but it does reduce the gap between medical devices and consumer electronics. For Demant, the question is therefore no longer only how small hearing aids can become, but how well they can be integrated into users\u2019 digital everyday lives. Over time, this could become important for both growth and pricing power.<\/p>\n
The half-year results should therefore first and foremost confirm that Demant continues to gain market share. After the share price recovery, expectations have also increased, leaving less room for disappointment. If growth remains clearly above the market, it strengthens the investment case. If momentum slows, however, investors may quickly start questioning how much of the recent progress reflects Demant\u2019s own execution and how much is due to uncertainty among competitors. Over the longer term, the product pipeline, AI and collaboration with the major technology platforms will become just as important.<\/p>\n","protected":false},"excerpt":{"rendered":"
Demant kommer med halv\u00e5rsregnskab i morgen efter en markant vending i aktien siden for\u00e5ret. En vigtig del af optimismen h\u00e6nger sammen med GN Store Nords aftale om at s\u00e6lge GN Hearing til italienske Amplifon for 17 mia. kr. Handlen ventes f\u00f8rst afsluttet mod slutningen af 2026, men usikkerheden hos en af Demants st\u00f8rste konkurrenter giver…<\/p>\n","protected":false},"author":158,"featured_media":1175575,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[1309],"tags":[],"asset_type":[],"class_list":["post-1284837","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-market-insights"],"acf":[],"yoast_head":"